Gentium Receives Negative Opinion From The CHMP On Defibrotide For The Treatment And Prevention Of VOD

VILLA GUARDIA, Italy, March 22, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has been informed by the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") that it has adopted a negative opinion, recommending the refusal of the marketing authorization for Defibrotide to treat and prevent hepatic veno-occlusive disease ("VOD") in adults and children undergoing hematopoietic stem cell transplantation therapy.

Gentium remains convinced of the favourable benefit/risk profile of Defibrotide, which is the only option recommended by the European Group for Blood and Marrow Transplantation for the treatment VOD, an unmet medical need where no agents are currently approved. In accordance with European regulations, the Company plans to appeal the EMA's decision and request a re-examination of the CHMP opinion.

EU patients will continue to have access to Defibrotide, under a named patient program ("NPP") where available.

European Medicines Agency press release can be accessed at www.ema.europa.eu .

The European Group for Blood Marrow Transplantation have also commented on this decision www.ebmt.org .

About the EMA Appeal Process

An Applicant has the right to request a re-examination of a CHMP recommendation no later than 15 days after receipt of the CHMP opinion. The Appeal procedure allows the Applicant 60 days to submit grounds for appeal. The CHMP has further 60 days to consider a revision of the initial opinion. An appeal would involve a re-examination of the application and must be based on the data already submitted. If an appeal is unsuccessful, the Company could resubmit a new application in the EU at a later date. More information can be obtained from the EMA website www.ema.europa.eu .   

About VOD

Veno-occlusive disease (VOD) is a potentially life-threatening condition, which typically occurs as a significant complication of stem cell transplantation. Certain high-dose conditioning regimens used as part of stem cell transplantation can damage the lining cells of hepatic blood vessels and result in VOD, a blockage of the small veins in the liver that leads to liver failure and can result in significant dysfunction in other organs such as the kidneys and lungs (so-called severe VOD). Stem cell transplantation is a frequently used treatment modality following high-dose chemotherapy and radiation therapy for hematologic cancers and other conditions in both adults and children. At present there is no approved agent for the treatment or prevention of VOD in the United States or the European Union.

If you liked this article you might like

Biotech 2013 by the Numbers: A Blockbuster Year

3 Biotech Stocks Spiking on Big Volume

3 Health Care Stocks Spiking on Big Volume

Trade-Ideas: Gentium SpA (GENT) Is Today's New Lifetime High Stock

4 Stocks Triggering Breakout Trades